AOD-9604 is a small fragment of human growth hormone — specifically the tail end (amino acids 176-191), the part associated with fat metabolism. It was engineered to capture growth hormone's fat-reducing signal while avoiding the broader effects of full growth hormone, such as raising IGF-1 or affecting blood sugar. That selective profile is the basis of its marketing.

Its safety profile in trials was actually fairly clean — it was generally well tolerated and, unlike full growth hormone or GH secretagogues, it does not appear to meaningfully raise IGF-1 or disrupt blood sugar. The irony is that the 'safe' part held up better than the 'effective' part: it's a relatively low-risk peptide that mostly didn't work for its intended purpose. Standard caveats still apply — limited long-term data and unverified gray-market purity.

How does AOD-9604 compare to GLP-1s for weight loss?

There is no comparison in terms of results. GLP-1 medications (semaglutide, tirzepatide) produce large, well-documented weight loss in rigorous trials. AOD-9604 largely failed to beat placebo for weight loss in its trials. If meaningful weight loss is the goal, AOD-9604 is not a substitute for a GLP-1 or for evidence-based approaches — see our GLP-1 options guide.

Is AOD-9604 FDA-approved or legal?

AOD-9604 is not an FDA-approved weight-loss drug — its development as one did not succeed. It has appeared in some other regulatory designations over the years (for example, food/ingredient contexts), but it is not approved as a fat-loss medication, and in the peptide market it's sold 'for research use only,' the usual unregulated gray-market channel with unverified purity.

AOD-9604: The Fat-Loss Peptide That Failed Its Trials

Q: Does AOD-9604 actually work for fat loss?

The honest answer is: the human evidence is disappointing. AOD-9604 was developed specifically as an anti-obesity drug, and its clinical trials in people largely failed to show meaningful weight loss beyond placebo. Animal data looked promising, which is why it advanced, but the human results did not deliver. So despite being marketed as a fat-loss peptide, its own weight-loss trials are the strongest argument against the hype.

An HGH fragment engineered to burn fat without raising IGF-1 or blood sugar — a clever idea that didn’t pan out. Here’s what it is, why its human obesity trials largely failed to beat placebo, and why “safe” ended up holding up better than “effective.”

HGH 176-191

A growth-hormone tail fragment

Trials failed

Largely didn't beat placebo for weight loss

No ↑ IGF-1

Doesn't raise IGF-1 / blood sugar like GH

Safe-ish

Well tolerated — but mostly ineffective

The headline, up front: AOD-9604 was developed specifically to be an anti-obesity drug, and its human clinical trials largely failed to produce meaningful weight loss beyond placebo. It’s marketed as a fat-loss peptide, but its own trials are the best evidence against the hype.

What AOD-9604 Is

AOD-9604 (“Advanced Obesity Drug 9604”) is a small fragment of human growth hormone — specifically the C-terminal tail, amino acids 176-191, the region associated with growth hormone’s fat-metabolism effects. The design idea was elegant: isolate the fat-burning signal of growth hormone while leaving out the rest, so you’d get lipolysis without raising IGF-1, affecting blood sugar, or the other systemic effects of full GH. That selective profile is exactly what the marketing leans on.

What the Evidence Actually Shows

Disappointing — human weight-loss trials largely failed

This is the crux. AOD-9604 advanced into human anti-obesity trials on the strength of promising animal data — and the human results were a letdown, with the compound largely failing to deliver clinically meaningful weight loss versus placebo. Development as a weight-loss drug did not succeed. When a compound built specifically to cause fat loss can’t beat placebo in its own trials, that’s about as clear a signal as this field offers.

Limited — other claimed uses (joint/cartilage) are exploratory

AOD-9604 has also been explored for cartilage/joint contexts, but that evidence is early and not a basis for confident use.

The Irony: “Safe” Held Up Better Than “Effective”

Here’s the genuinely interesting part. The safety side of AOD-9604’s pitch actually held: in trials it was generally well tolerated, and — unlike full growth hormone or GH secretagogues such as sermorelin, ipamorelin, or CJC-1295 — it does not appear to meaningfully raise IGF-1 or disrupt blood sugar. So it largely avoids the GH-axis cancer-signaling and glucose concerns that those compounds carry. The catch is that it’s a relatively low-risk peptide that mostly didn’t work for its intended purpose — a rare case where the safety claim outlasted the efficacy claim.

AOD-9604 vs. What Actually Works for Weight Loss

If meaningful weight loss is the goal, there’s no contest: GLP-1 medications (semaglutide, tirzepatide, retatrutide) produce large, trial-proven results, while AOD-9604 largely failed to beat placebo. AOD-9604 is not a substitute for a GLP-1, and it’s certainly not a substitute for the fundamentals. See our GLP-1 options guide and weight-loss peptides guide for the evidence-based landscape.

Risks & Practical Notes

The main “risk” is opportunity cost — spending money and hope on a compound its own trials suggest doesn’t do much.
Limited long-term human data, as with most peptides.
Unregulated supply. Gray-market AOD-9604 is of unverified purity — see where to get peptides tested.
Not FDA-approved as a weight-loss drug; its development as one did not succeed.

The Honest Bottom Line

AOD-9604 is a clever idea — the fat-burning piece of growth hormone, minus the GH baggage — with a reassuring safety profile and a disappointing efficacy record. Its own human trials largely failed to show meaningful weight loss, so the marketing is running well ahead of the data. If your goal is real weight loss, your effort and money are far better spent on approaches with actual evidence. AOD-9604 is mostly notable as a cautionary example of a peptide whose pitch outlived its proof.

Frequently Asked Questions

Does AOD-9604 actually work for fat loss?

The human evidence is disappointing — it was built as an anti-obesity drug and its trials largely failed to beat placebo. Marketed as fat-loss, but its own trials argue against the hype.

What is it?

A fragment of human growth hormone (amino acids 176-191) designed to capture GH’s fat-metabolism effect without raising IGF-1 or affecting blood sugar.

Is it safe?

Its safety profile was relatively clean — well tolerated, no meaningful IGF-1/glucose effects. The irony is the “safe” part held up better than the “effective” part.

How does it compare to GLP-1s?

No comparison — GLP-1s produce large, proven weight loss; AOD-9604 largely failed to beat placebo. Not a substitute.

Is it FDA-approved/legal?

Not approved as a weight-loss drug (development didn’t succeed); sold “research use only” with unverified purity.

This guide is general legal and educational information, not legal or medical advice, and does not create an attorney-client or physician-patient relationship. It is written by a California-licensed attorney, not a physician. AOD-9604 is not an FDA-approved weight-loss drug; its clinical development as one did not succeed. Research peptides sold “for research use only” are not approved for human use. For weight management, consult a licensed clinician about evidence-based options. Verify current information before relying on it. Current as of June 20, 2026.